Understanding a 32% Prothrombin Time Result
A "32% Prothrombin Time" refers to prothrombin activity expressed as a percentage of normal, indicating that the patient has approximately 32% of normal coagulation factor activity—this represents significantly reduced clotting function and suggests either severe factor deficiency (factors II, V, VII, X, or fibrinogen) or the presence of an inhibitor.
What This Value Represents
The percentage format is one of several ways PT results have historically been reported 1. This reporting method expresses the patient's coagulation factor activity as a percentage compared to normal pooled plasma (where 100% would be normal activity).
Key Clinical Interpretation Points:
- 32% activity = markedly prolonged clotting time
- Normal prothrombin activity is typically 70-130%
- Values below 40% indicate significant coagulopathy 2
- Historical data suggests spontaneous bleeding typically occurs when factor VII activity falls below 10%, while thrombosis risk increases above 40% 2
Clinical Context Matters Critically
The interpretation and clinical significance of this result depends entirely on whether the patient is on vitamin K antagonist (VKA) therapy:
If Patient is on Warfarin/VKA:
- This level (32%) falls within or near historical therapeutic ranges
- Corresponds roughly to 10-40% prothrombin activity, which was the target range used in early warfarin monitoring 2
- Should be correlated with INR for proper therapeutic assessment
- The PT/INR system was specifically designed and validated ONLY for VKA monitoring 2
If Patient is NOT on VKA:
- This represents a pathologic coagulopathy requiring investigation
- Possible causes include:
- Liver disease (reduced synthesis of clotting factors)
- Vitamin K deficiency
- Congenital factor deficiencies
- Acquired inhibitors
- Consumptive coagulopathy (DIC)
Critical Pitfall to Avoid
Do not automatically transfuse plasma based solely on this number, especially if the patient is asymptomatic. The evidence is clear that plasma transfusion provides no clinical benefit for asymptomatic patients with mildly to moderately elevated PT/INR values and can cause harm 2. The INR and PT percentage were designed for VKA monitoring, not as general predictors of bleeding risk in other conditions 2.
Recommended Next Steps:
Verify the result isn't artifactual:
- Check for proper sample collection (correct citrate ratio)
- Polycythemia can cause falsely prolonged PT due to excess citrate 3
- Ensure adequate sample volume and mixing
Perform mixing study to differentiate factor deficiency from inhibitor 4, 5:
- Mix patient plasma 1:1 with normal pooled plasma
- ≥70% correction suggests factor deficiency
- <70% correction suggests inhibitor presence
Obtain specific factor assays if deficiency is suspected
Assess clinical bleeding risk based on patient symptoms, not just the laboratory number—PT percentage is a poor predictor of procedural bleeding in non-VKA patients 2
Modern Reporting Standards
Most laboratories now report PT as INR (for VKA patients) or as seconds with ratio (for non-VKA patients) rather than percentage 1. The percentage format, while historically used, has largely been replaced because it can be confusing and lacks standardization across different thromboplastin reagents.